Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807991 | PMC |
| http://dx.doi.org/10.3389/fvets.2025.1543814 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial for "Hemispheric Asymmetry of Neuromelanin-Iron Dysfunction in the Substantia Nigra: MRI-Based Evidence for Lateralized Motor Onset in Early-Stage Parkinson's Disease".
J Magn Reson Imaging
September 2025
Neuroimaging Laboratory, School of Medicine, University of Navarra, Pamplona, Spain.
Navigating disclosure in new romantic partnerships as an adolescent or young adult with Li-Fraumeni syndrome.
Fam Cancer
September 2025
School of Social Policy and Practice, University of Pennsylvania, Philadelphia, USA.
Li-Fraumeni syndrome (LFS) is an early-onset cancer syndrome caused by pathogenic germline TP53 variants. Adolescents and young adults (AYAs) with LFS may have challenges navigating new romantic partnerships given the significant effects of LFS on multiple life domains that also affect partners (e.g.
View Article and Find Full Text PDFEditorial for "MR Passive Elastography: From Seismic Noise Tomography to Brain Tumors Characterization".
J Magn Reson Imaging
September 2025
Department of Magnetic Resonance Imaging, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Editorial for "Development of an MRI-Based Comprehensive Model Fusing Clinical, Habitat Radiomics, and Deep Learning Models for Preoperative Identification of Tumor Deposits in Rectal Cancer".
J Magn Reson Imaging
September 2025
Department of Surgery, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE.
Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer's defenses.
Front Immunol
September 2025
Department of Pathological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, United States.
Oncolytic virotherapy (OVT) has emerged as a promising and innovative cancer treatment strategy that harnesses engineered viruses to selectively infect, replicate within, and destroys malignant cells while sparing healthy tissues. Beyond direct oncolysis, oncolytic viruses (OVs) exploit tumor-specific metabolic, antiviral, and immunological vulnerabilities to reshape the tumor microenvironment (TME) and initiate systemic antitumor immunity. Despite promising results from preclinical and clinical studies, several barriers, including inefficient intratumoral virus delivery, immune clearance, and tumor heterogeneity, continue to limit the therapeutic advantages of OVT as a standalone modality and hindered its clinical success.
View Article and Find Full Text PDF